This project is aimed at developing novel synthetic compounds capable of stabilizing platelet membranes. One of the major thrusts is directed at aiding individuals especially predisposed to thromboembolic complicating resulting from their blood's exposure to biomaterials like implanted prosthetic devices and extracorporeal equipment. In this proposal, novel molecular entities will be obtained using a three-pronged approach: (i) because of the importance of enantioselectivity in drug action, each of the 3 most active compounds from their previous investigation will be resolved into its 3 stereoisomers. The individual enantiomers and diastereomers will be tested for their inhibitory effects on human blood platelet aggregation in vitro, induced by human alpha-thrombin, collagen, and epinephrine. (ii) Racemic analogues of the 3 compounds will be synthesized in order to extend their duration of action, and (iii) hydrophbiaity and electron density will be optimized in structural components not previously examined. Compounds showing reasonable potency in preliminary screening will be evaluated for their effects in vitro, (a) on cytosolic ionized calcium ([Ca. 2+]) concentrations, (b) on levels of platelet factor 4 (PF-4), platelet factor 3 (PF-3) and serotonin, and (c) for acute toxicity in vivo, in mice. In cooperation with Dr. Larry V. McIntire, at Rice University, the impact of selected compounds will be studied on the kinetics of human blood platelet adhesion and thrombus growth effected by collagen and biomaterials in his parallel plate flow chamber system. One or two highly active and least toxic compounds will be tested for platelet aggregation inhibitory activity, ex vivo, in dogs. The pharmacokinetics of the same compounds will be evaluated in mice and dogs, and bioavailibility in dogs. Structure of metabolites found in urine will be established using HPLC-MS. Due to the chiral environment of many biological systems, delineation of the enantio-selectivity of these synthetic compounds is expected to uncover increased antithrombotic potency which, at the same time, could register lesser toxicity. Identification of the structural features associated with metabolic inactivation would provide leads to the eventual design of highly active molecules with optimal duration of action. Relating structural features of the synthetic compounds to their influence on thrombocyte response should permit interpretation of human blood platelet response patterns in terms of chemical parameters, and to 'fine- tune' molecular segments toward optimal activity.

Agency
National Institute of Health (NIH)
Institute
National Heart, Lung, and Blood Institute (NHLBI)
Type
Research Project (R01)
Project #
5R01HL022236-14
Application #
3336776
Study Section
Surgery and Bioengineering Study Section (SB)
Project Start
1979-04-01
Project End
1995-07-31
Budget Start
1993-08-01
Budget End
1994-07-31
Support Year
14
Fiscal Year
1993
Total Cost
Indirect Cost
Name
University of Tennessee Health Science Center
Department
Type
Schools of Pharmacy
DUNS #
941884009
City
Memphis
State
TN
Country
United States
Zip Code
38163
Guo, Z; Zheng, X; Thompson, W et al. (2000) New carbamoylpiperidines as human platelet aggregation inhibitors. Bioorg Med Chem 8:1041-58
Han, G; Bannerman, D; Handa, R K et al. (1997) Antiplatelet effects of R,S-(meso)-alpha, alpha'-bis[3-(N,N-diethylcarbamoyl) piperidino]-p-xylene ex vivo in the dog and in vivo in the mouse. Gen Pharmacol 28:617-21
Gir, S; Reavis, R; Turitto, V T et al. (1996) Antiplatelet agents affecting the interaction of Tissue Factor-Factor VIIa complex with Factor X in a continuous-flow reactor. Biotechnol Appl Biochem 23 ( Pt 1):63-6
Handa, R K; Dillingham, E O; Gollamudi, R (1995) Antithrombotic nipecotamide increases cyclic AMP levels and inhibits protein phosphorylation in human platelets. Life Sci 57:983-8
Herron, D; Dillingham, E O; Lyman, B A et al. (1995) Inhibition of PAF-induced human platelet aggregation by antithrombotic nipecotomides. Prostaglandins Leukot Essent Fatty Acids 52:309-18
Zheng, X; Day, C; Gollamudi, R (1995) Synthesis of stereoisomers of antithrombotic nipecotamides. Chirality 7:90-5
Zheng, X; Salgia, S R; Thompson, W B et al. (1995) Design and synthesis of piperidine-3-carboxamides as human platelet aggregation inhibitors. J Med Chem 38:180-8
Lawrence, W H; Howell, R D; Gollamudi, R (1994) Antiplatelet activity of nipecotamides in experimental thrombosis in mice. J Pharm Sci 83:222-5
Gollamudi, R; Dillingham, E O; Bond, S E (1994) Inhibition of agonist-induced rise in platelet Ca2+ by antithrombotic nipecotamides. Blood Coagul Fibrinolysis 5:375-83
Han, G; Bond, S E; Lawrence, W H et al. (1994) Synergistic antiplatelet effects of a nipecotamide A-1C and low dose aspirin. Gen Pharmacol 25:1373-9

Showing the most recent 10 out of 31 publications